Rishi P. Singh, MD (Shaker Heights, OH), Oswaldo FM Brasil, MD (Cleveland, OH), Anat Galor, MD (Cleveland, Ohio), Scott D Smith, MD, MPH (Cleveland, OH), Careen Y. Lowder, MD (Cleveland, OH), Jonathan E. Sears, MD (Cleveland, OH), Peter K. Kaiser, MD (Cleveland, OH)

PURPOSE:

To evaluate the predictive factors for visual outcome after intravitreal triamcinolone acetonide injection in the treatment of diabetic macular edema.

METHODS:

Retrospective chart review of patients with diabetic macular edema who met the following inclusion criteria: clinically significant diabetic macular edema, receipient of a 4mg/0.1ml intravitreal triamcinolone acetonide injection, and optical coherence tomography of the macula performed up to ten days prior to injection. All patients received a full ophthalmic examination including best-corrected Snellen visual acuity. The main outcome measure was mean change in vision three months after injection.

RESULTS:

Multivariate linear regression analysis included 52 eyes of 42 patients. Mean change in vision three months after  injection was significantly related to baseline visual acuity (-0.267 logMAR, P=0.002), presence of cystoid macular edema (0.146 logMAR, P=0.03) and interaction of epiretinal membrane and baseline visual acuity (0.282 logMAR, P=0.0008). The presence of subretinal fluid was highly suggestive of clinical correlation, but not statistically
significant (-0.170 logMAR, P=0.06). Vision change three months after injection was statistically independent (P>0.1) of all other studied variables.

CONCLUSION:

OCT characteristics and baseline visual acuity is useful in predicting visual outcomes 3 months after intravitreal triamcinolone acetonide injection for DME.